Complete Genomics is a leader in whole human genome sequencing based in Mountain View, California. Using its proprietary sequencing instruments, chemistry, and software, the company has sequenced more than 20,000 whole human genomes over the past five years. The company’s mission is to improve human health by providing researchers and clinicians with the core technology and commercial systems to understand, prevent, diagnose, and treat diseases and conditions.
Complete Genomics was founded in 2006 by Dr. Clifford Reid and Dr. Radoje (Rade) Drmanac. It is currently a company of 300+ employees spanning multiple specialties: genomics, hardware engineering, biochemistry, molecular biology, bioinformatics, software, semiconductors, and operations.
In March 2013 Complete Genomics was acquired by BGI-Shenzhen , the world’s largest genomics services company. BGI is a 5,000-person company headquartered in Shenzhen, China that provides comprehensive sequencing and bioinformatics services for commercial science, medical, agricultural and environmental applications. BGI and its customers have generated over 250 publications in top-tier journals including Cell, Science, and Nature. BGI is recognized globally as an innovator for conducting collaborative projects globally with leading research institutions.
Prior to the acquisition by BGI, Complete Genomics was focused on selling whole genome sequencing services to over 150 research customers. Completion of the acquisition set the stage for the strategic expansion of our capabilities as a global system provider, with a shared company culture of deep collaboration and cooperation. Complete Genomics is now focused on building a new generation of high-throughput sequencing technology and developing new and exciting research, clinical and consumer applications.
In 2015 Complete Genomics introduced the Revolocity™ system, the first end-to-end genomics solution for large-scale, high-quality genomes. Revolocity is the first in a line of systems that we intend to commercialize. With strong financial backing and a pipeline of platforms and novel technologies in development, we remain committed to providing advanced life science technologies serving the research and clinical markets.